Search Results | Blood | American Society of Hematology

1-20 of 157

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant

Blood (2022) 139 (18): 2758–2769.

DOI: https://doi.org/10.1182/blood.2021014255

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients

Blood blood.2021014520.

DOI: https://doi.org/10.1182/blood.2021014520

Published: 2022

Includes: Supplemental data

Journal Articles

Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study

Blood (2021) 138 (Supplement 1): 883.

DOI: https://doi.org/10.1182/blood-2021-147568

Published: 2021

Journal Articles

Highly Selective Irreversible ITK Inhibitor Cpi-818 Reduces Acute Graft-Versus Host Disease

Sarah Lindner, Nicole Lee, Gabriel K Armijo, Marina D Burgos da Silva, Pamela S Herrera, Chi L Nguyen, Emmanuel A Dwomoh, Romina Ghale, Melody Smith, Miguel-Angel Perales, Kate A Markey, Joseph J Buggy, James W Janc, Marcel van den Brink

Blood (2021) 138 (Supplement 1): 3814.

DOI: https://doi.org/10.1182/blood-2021-153360

Published: 2021

Journal Articles

A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Peter A. Riedell, Jamie Brower, Loretta Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Joseph P. McGuirk, Veronika Bachanova, Wei-Ting Hwang, Stephen J. Schuster, Michael R. Bishop, David L. Porter

Blood (2021) 138 (Supplement 1): 2512.

DOI: https://doi.org/10.1182/blood-2021-151971

Published: 2021

Journal Articles

Phase 1/2 Study of Nexi-001 Donor-Derived Multi-Antigen Specific CD8+ T Cells for the Treatment of Relapsed Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Transplantation

Monzr M. Al Malki, Sumithira Vasu, Dipenkumar Modi, Miguel-Angel Perales, Lucy Y Ghoda, Donna Bui, Vineetha Edavana, Emily Lu, Sojung Kim, Lauren Suarez, Mathias Oelke, Daniel Bednarik, Robert D Knight, Juan C. Varela

Blood (2021) 138 (Supplement 1): 4819.

DOI: https://doi.org/10.1182/blood-2021-152419

Published: 2021

Journal Articles

Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines

Roni Tamari, Ioannis Politikos, David Knorr, Santosha Vardhana, Jennifer Young, Leeann Marcello, Sital Doddi, Sean M Devlin, Lakshmi Ramanathan, Melissa S. Pessin, Erica Dunn, Meighan A. Palazzo, Christina Bravo, Genovefa A. Papanicolaou, Mini Kamboj, Miguel-Angel Perales, David J. Chung, Gunjan L Shah

Blood (2021) 138 (Supplement 1): 3891.

DOI: https://doi.org/10.1182/blood-2021-151376

Published: 2021

Journal Articles

Interim Results of a Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

Alina Markova, Alexander Pan, Stephen Dusza, Arifa Chowdhury, Oluwaseun Kukoyi, Miguel-Angel Perales, Mario Lacouture, Susan Prockop, Doris M Ponce

Blood (2021) 138 (Supplement 1): 3915.

DOI: https://doi.org/10.1182/blood-2021-144743

Published: 2021

Journal Articles

A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma

Jae H Park, Craig S. Sauter, M. Lia Palomba, Gunjan L Shah, Parastoo B Dahi, Richard J Lin, Michael Scordo, Connie Lee Batlevi, Miguel-Angel Perales, Peter Kane, Aishat Olaide Afuye, Elena Mead, Bianca Santomasso, Elizabeth Halton, Michel Sadelain, Renier J Brentjens

Blood (2021) 138 (Supplement 1): 96.

DOI: https://doi.org/10.1182/blood-2021-150431

Published: 2021

Journal Articles

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2.

DOI: https://doi.org/10.1182/blood-2021-148039

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation

Antonio M. Jimenez, Miguel-Angel Perales, Sean M Devlin, Lazaros J. Lekakis, Craig S. Sauter, Denise Pereira, Amer Beitinjaneh, Samantha Brown, Trent Wang, Doris M Ponce, Mark S. Goodman, Stephanie Chinapen, Krishna V. Komanduri, Brian C Shaffer

Blood (2021) 138 (Supplement 1): 1814.

DOI: https://doi.org/10.1182/blood-2021-150714

Published: 2021

Journal Articles

Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium

Kitsada Wudhikarn, Ana Alarcon Tomas, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Joseph P. McGuirk, Loretta Nastoupil, David L. Porter, Peter A. Riedell, Miguel-Angel Perales

Blood (2021) 138 (Supplement 1): 2843.

DOI: https://doi.org/10.1182/blood-2021-150012

Published: 2021

Journal Articles

Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study

Cameron J. Turtle, Elizabeth Budde, Krina K. Patel, Miguel-Angel Perales, Andrew J. Cowan, Hayder Saeed, Julio C. Chavez, Alexandre V. Hirayama, Delaney R. Kirchmeier, Murali Janakiram, Kai Wu, Lawrence Fong, Zachary Lee, Neha Dixit, Xiaoli Wang, Kazuharu Kai, Mario Q. Marcondes, Jonathan Zalevsky, Nina Shah

Blood (2021) 138 (Supplement 1): 2815.

DOI: https://doi.org/10.1182/blood-2021-147350

Published: 2021

Journal Articles

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Blood (2021) 138 (Supplement 1): 3134.

DOI: https://doi.org/10.1182/blood-2021-147758

Published: 2021

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

Blood (2021) 138 (Supplement 1): 3880.

DOI: https://doi.org/10.1182/blood-2021-148652

Published: 2021

Journal Articles

Nutrition As a Predictor of Microbiome Injury in Allo-HCT

Anqi Dai, Peter A. Adintori, Melissa D Docampo, Corrado Zuanelli Brambilla, Marissa L. Buchan, Antonio L.C. Gomes, Marina D Burgos da Silva, Kate A Markey, Sean M Devlin, Annelie Clurman, John B Slingerland, Abigail J. Johnson, Dan Knights, Robert R. Jenq, Sergio A Giralt, Miguel-Angel Perales, Marcel van den Brink, Jonas Schluter, Jonathan U Peled

Blood (2021) 138 (Supplement 1): 746.

DOI: https://doi.org/10.1182/blood-2021-150762

Published: 2021

Journal Articles

TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 710.

DOI: https://doi.org/10.1182/blood-2021-145158

Published: 2021

Journal Articles

Five-Year Experience Using Bridging Radiotherapy Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapies for B-Cell Malignancies at Memorial Sloan Kettering Cancer Center

Blood (2021) 138 (Supplement 1): 2507.

DOI: https://doi.org/10.1182/blood-2021-151179

Published: 2021

Journal Articles

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Frederick L. Locke, Caron Jacobson, Long Ma, Hua Dong, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel-Angel Perales, Matthew A. Lunning, Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Abu-Sayeef Mirza, Sarah Nikiforow, Hairong Xu, Marcelo C Pasquini

Blood (2021) 138 (Supplement 1): 530.

DOI: https://doi.org/10.1182/blood-2021-149679

Published: 2021

Journal Articles

Lesion Characteristics and Patterns of Failure in Diffuse Large B Cell Lymphoma Patients Treated with Bridging Radiotherapy Prior to Chimeric Antigen Receptor T Cell Therapy

Blood (2021) 138 (Supplement 1): 1429.

DOI: https://doi.org/10.1182/blood-2021-149702

Published: 2021

2 3 4 5

NARROW

Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients

Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study

Highly Selective Irreversible ITK Inhibitor Cpi-818 Reduces Acute Graft-Versus Host Disease

A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Phase 1/2 Study of Nexi-001 Donor-Derived Multi-Antigen Specific CD8+ T Cells for the Treatment of Relapsed Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Transplantation

Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines

A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation

Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium

Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

Nutrition As a Predictor of Microbiome Injury in Allo-HCT

TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma

Five-Year Experience Using Bridging Radiotherapy Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapies for B-Cell Malignancies at Memorial Sloan Kettering Cancer Center

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Lesion Characteristics and Patterns of Failure in Diffuse Large B Cell Lymphoma Patients Treated with Bridging Radiotherapy Prior to Chimeric Antigen Receptor T Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only